Signal #128799 · SEC 8-K

$MLTX SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $MLTX filing catalyst

Why did $MLTX trigger an AI stock catalyst alert?

$MLTX triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +3.5/10). Headline: MoonLake Submits BLA for Sonelokimab, Reports Q3 Net Loss of $79.5M. Key points: - BLA submitted to FDA for sonelokimab in hidradenitis suppurativa; commercial launch targeted for H2 2027. - Q3 net loss increased to $79.5M (vs $61.8M prior quarter) driven by $68.9M R&D expenses. - Cash reserves stand at $379.7M, providing operational runway into mid-2028.

How did $MLTX stock react after the SEC filing?

After the SEC 8-K for $MLTX, observed market reaction: T0 price $11.70. Past moves do not guarantee future results.

Where can I get real-time $MLTX SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $MLTX via Telegram and the VIP Web Terminal from €10/month.

$MLTX

$MLTX – MoonLake Submits BLA for Sonelokimab, Reports Q3 Net Loss of $79.5M

MoonLake Immunotherapeutics

2026-11-04 00:00:00 UTC · SEC 8-K · All $MLTX

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+3.5 / 10)

BLA submitted to FDA for sonelokimab in hidradenitis suppurativa; commercial launch targeted for H2 2027.
Q3 net loss increased to $79.5M (vs $61.8M prior quarter) driven by $68.9M R&D expenses.
Cash reserves stand at $379.7M, providing operational runway into mid-2028.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →